Daiwa Securities Group Inc. Affimed N.V. Transaction History

Daiwa Securities Group Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 05, 2021	BUY	$5.54 - $7.51 $1,224 - $1,659	221 Added 118.82%	407 $3,000
Q4 2020 Feb 04, 2021	SELL	$3.16 - $7.03 $771 - $1,715	-244 Reduced 56.74%	186 $1,000
Q1 2020 May 14, 2020	BUY	$1.44 - $3.02 $619 - $1,298	430 New	430 $1,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $5.97M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

Stay updated on Daiwa Securities Group Inc. with notifications on news.